Our TLR7 lead candidate MBS8 is a micelle formulation of a small molecule TLR7 agonist with the unique selling points:

  • Administered by the intravenous route to target multiple cancer types
  • Targeting the intracellular TLR7 receptor
  • Simple and scalable GMP production
  • Potent anti-tumor activity as monotherapy and in combination with anti-PD-1, radiotherapy and chemotherapy
  • Favourable safety profile